Delisting risk
Jasper Therapeutics
Develops complement inhibitors and targeted antibodies for immunological disorders.
$0.7140
After-hours close+0.02 (+3.02%)
At close$0.6931(−0.87%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.08 | — | — |
| Aug 2026 | −$0.27 | −$0.10 | +62.7% |
| Aug 2026 | −$0.27 | −$0.10 | +62.7% |
| May 2026 | −$0.46 | −$0.38 | +17.4% |
| Mar 2026 | −$0.79 | −$0.32 | +59.5% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.08 | — | — | $12.0M | — | — |
| Aug 14, 2026 | −$0.27 | −$0.10 | +62.7% | — | — | — |
| Aug 13, 2026 | −$0.27 | −$0.10 | +62.7% | — | — | — |
| May 14, 2026 | −$0.46 | −$0.38 | +17.4% | — | — | — |
| Mar 30, 2026 | −$0.79 | −$0.32 | +59.5% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Nov 10, 2025 | ||||||
| Aug 13, 2025 | ||||||
| May 12, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 4, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 11, 2023 | ||||||
| May 12, 2023 | ||||||
| Mar 8, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 12, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 18, 2022 | ||||||
| Nov 12, 2021 | ||||||
| Aug 16, 2021 | ||||||
| May 24, 2021 | ||||||
| Mar 30, 2021 | ||||||
| Nov 10, 2020 | ||||||
| Aug 14, 2020 | ||||||